Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 31;16(3):613.
doi: 10.3390/cancers16030613.

Emerging Therapies in Management of Cholangiocarcinoma

Jessica Speckart  1 , Veronica Rasmusen  1 , Zohray Talib  2 , Dev A GnanaDev  3 , Amir A Rahnemai-Azar  4
Affiliations
Review

Emerging Therapies in Management of Cholangiocarcinoma

Jessica Speckart et al. Cancers (Basel). .

Abstract

Cholangiocarcinoma is a heterogeneous group of biliary tract cancers that has a poor prognosis and globally increasing incidence and mortality. While surgical resection remains the only curative option for the treatment of cholangiocarcinoma, the majority of cancers are unresectable at the time of diagnosis. Additionally, the prognosis of cholangiocarcinoma remains poor even with the current first-line systemic therapy regimens, highlighting the difficulty of treating locally advanced, metastatic, or unresectable cholangiocarcinoma. Through recent developments, targetable oncogenic driver mutations have been identified in the pathogenesis of cholangiocarcinoma, leading to the utilization of molecular targeted therapeutics. In this review, we comprehensively discuss the latest molecular therapeutics for the treatment of cholangiocarcinoma, including emerging immunotherapies, highlighting promising developments and strategies.

Keywords: biliary tract cancer; cholangiocarcinoma; genomic aberration; genomics; immunotherapy; molecular targeted therapies; precision medicine; systemic therapy; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Notable signaling pathways implicated in the progression of cholangiocarcinoma. Used with permission from [5].
See this image and copyright information in PMC

References

    1. Cholangiocarcinoma. Nat. Rev. Dis. Prim. 2021;7:66. doi: 10.1038/s41572-021-00305-x. - DOI - PMC - PubMed
    1. Bertuccio P., Malvezzi M., Carioli G., Hashim D., Boffetta P., El-Serag H.B., La Vecchia C., Negri E. Global Trends in Mortality from Intrahepatic and Extrahepatic Cholangiocarcinoma. J. Hepatol. 2019;71:104–111. doi: 10.1016/j.jhep.2019.03.013. - DOI - PubMed
    1. Banales J.M., Marin J.J.G., Lamarca A., Rodrigues P.M., Khan S.A., Roberts L.R., Cardinale V., Carpino G., Andersen J.B., Braconi C., et al. Cholangiocarcinoma 2020: The next Horizon in Mechanisms and Management. Nat. Rev. Gastroenterol. Hepatol. 2020;17:557–588. doi: 10.1038/s41575-020-0310-z. - DOI - PMC - PubMed
    1. Valle J., Wasan H., Palmer D.H., Cunningham D., Anthoney A., Maraveyas A., Madhusudan S., Iveson T., Hughes S., Pereira S.P., et al. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. N. Engl. J. Med. 2010;362:1273–1281. doi: 10.1056/NEJMoa0908721. - DOI - PubMed
    1. Chong D.Q., Zhu A.X. The Landscape of Targeted Therapies for Cholangiocarcinoma: Current Status and Emerging Targets. Oncotarget. 2016;7:46750–46767. doi: 10.18632/oncotarget.8775. - DOI - PMC - PubMed

LinkOut - more resources